3 ms·

This recent drug does better than 3-6 months: Nivolumab . One-Third of Patients With Advanced Melanoma Survive at Least 5 Years After Nivolumab Treatment. (htt

This recent drug does better than 3-6 months: Nivolumab . One-Third of Patients With Advanced Melanoma Survive at Least 5 Years After Nivolumab Treatment. (https://www.ascopost.com/issues/may-10-2016/one-third-of-patients-with-advanced-melanoma-survive-at-least-5-years-after-nivolumab-treatment/ https://www.ascopost.com/issues/may-10-2016/one-third-of-pat... Here's another recent success : https://hcp.lutathera.com/ https://hcp.lutathera.com/ --- https://www.nejm.org/doi/full/10.1056/NEJMoa1607427 https://www.nejm.org/doi/full/10.1056/NEJMoa1607427 At the data-cutoff date for the primary analysis, the estimated rate of progression-free survival at month 20 was 65.2% (95% confidence interval [CI], 50.0 to 76.8) in the 177Lu-Dotatate group and 10.8% (95% CI, 3.5 to 23.0) in the control group. Lutathera delivers a radioactive molecule to the tumor.

m0zg 7y ago
$150K+/yr. OOF. On the positive side, 20 years from now these drugs will be dollar a bucket as generics. Thank god for capitalism.
- _jal 7y ago
  No, it won't. Look at inulin prices. Or pharma-bro's Daraprim. That's what capitalism does to generics.
  - m0zg 7y ago
    Not really. Regarding insulin, that's what _the lack of capitalism_ does to generics. You can't import insulin into the US, and that's why it's so expensive here. Daraprim wasn't generic until literally 5 days ago: https://www.biospace.com/article/fda-approves-first-generic-for-daraprim-the-drug-martin-shkreli-increased-the-price-of-by-5-000-percent-/ https://www.biospace.com/article/fda-approves-first-generic-...